Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry ...

Detailed price information for Relay Therapeutics Inc (RLAY-Q) from The Globe and Mail including charting and trades.

BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-202511.1-month median PFS in heavily pre-treated ...

Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant Initial Phase 1/2 data of zovegalisib + ...

CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (RLAY) (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing ...

Relay Therapeutics develops precision medicines targeting oncology and genetic diseases, leveraging proprietary computational technology.

Relay Therapeutics is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay's Dynamo® ...

This clinical-stage biotech focused on precision oncology therapies reported an insider sale amid a year of sharp share price gains.

The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link ...